Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement - Chortis, V; Taylor, A E; Schneider, P (J Clin Endocrinol Metab, 2013)
et al.